Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Relative Value

The Relative Value of one Suzhou Zelgen Biopharmaceuticals Co Ltd stock under the Base Case scenario is 63.71 CNY. Compared to the current market price of 64.04 CNY, Suzhou Zelgen Biopharmaceuticals Co Ltd is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
63.71 CNY
Overvaluation 1%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
25
Median 3Y
35
Median 5Y
35.5
Industry
7.7
Forward
27.6
vs History
vs Industry
Median 3Y
-37.9
Median 5Y
-41.3
Industry
22.7
Forward
-113.2
vs History
1
vs Industry
Median 3Y
-31.5
Median 5Y
-37.7
Industry
21.6
vs History
16
vs Industry
2
Median 3Y
-18.7
Median 5Y
-37.5
Industry
25.2
vs History
41
vs Industry
9
Median 3Y
9.2
Median 5Y
9.7
Industry
2.5
vs History
33
vs Industry
23
Median 3Y
32.4
Median 5Y
32.7
Industry
7.7
Forward
25.3
vs History
33
vs Industry
17
Median 3Y
34.8
Median 5Y
35.2
Industry
9
vs History
vs Industry
Median 3Y
-29.5
Median 5Y
-32.3
Industry
4.2
Forward
-250.8
vs History
vs Industry
Median 3Y
-29.5
Median 5Y
-32.3
Industry
4.1
Forward
-66.5
vs History
1
vs Industry
Median 3Y
-28.8
Median 5Y
-33.8
Industry
5.7
vs History
vs Industry
Median 3Y
-27.6
Median 5Y
-30.9
Industry
3.6
vs History
41
vs Industry
11
Median 3Y
22
Median 5Y
24.8
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
17B CNY 41.6 -73.4 -52.1 -52.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 10.9 -242.3 24.1 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.9 17.5 15.9 17.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.8B EUR 18.7 -131 -105.5 -76.9
P/E Multiple
Earnings Growth
CN
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Average P/E: 208.2
Negative Multiple: -73.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Average EV/EBITDA: 17.2
Negative Multiple: -52.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Average EV/EBIT: 22.5
Negative Multiple: -52.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

See Also

Discover More
Back to Top